NorthSea Therapeutics NASH Virtual KOL Call
Virtual NASH KOL call with Dr. John Kastelein, MD, PhD and NorthSea Therapeutics
December 15, 11am-12pm
- The importance of targeting cardiovascular risk factors in patients with NASH
- The effects of icosabutate on cardiovascular risk factors in overweight, dyslipidemic subjects
- Inflammation as a common driver of both NASH and CVD
John Kastelein, MD, PhD:
Dr. John Kastelein is professor of medicine, chairman of the department of vascular medicine, and holds the Strategic Chair of Genetics in Cardiovascular Disease at the Academic Medical Center of the University of Amsterdam. Dr. Kastelein is a member of the Steering Committees of numerous lipid lowering and cardiovascular intervention trials. His main interest is in the development of novel therapies for Cardiovascular Diseases and the genetic basis of dyslipidemia.